Glioblastoma (GBM) is the most common malignant primary brain tumor. It still carries a grim prognosis and new therapies are needed. This review summarizes the current status of mechanistic insights into the function of extracellular regulated kinase (ERK) and its potential as a therapeutic target for patients with GBM. Currently, some promising ERK inhibitors are in clinical trials in tumor entities other than GBM. Here, we provide a comprehensive overview on the functions of ERK1/2 in GBM and a rationale for treatment of GBM with ERK inhibitors.
INTRODUCTION
Glioblastoma (GBM) is the most common malignant primary brain tumor. Despite aggressive standard therapy consisting of surgery followed by adjuvant radiation and chemotherapy, the median survival remains 14-15 months (1, 2) . Moreover, GBM is characterized by rapid cell proliferation, resistance to drug-induced apoptosis, an aggressive infiltration into surrounding brain tissue and a high rate of recurrence.
Although having a heterogeneous genetic profile, there are some common features that promote GBM progression. On the basis of genetic profiles and mutations in key genes, The Cancer Genome Atlas defined 4 oncogenic GBM subtypes: (1) the classical subtype, characterized by high expression levels of EGFR; (2) the proneural GBM subtype with frequent mutations in p53 and IDH; (3) the mesenchymal subgroup with common mutations in the tumor suppressor NF1; and (4) a neural subgroup with no specific gene mutations but with expression levels of genes that are also typical for normal brain tissue (3) . Beyond these GBM onco-signatures, a common feature of all GBM types is an aberrant kinase signaling. Among them, overactivation of PI3K/Akt and the mitogen-activated protein kinase (MAPK) family, 2 extracellular regulated kinases, extracellular regulated kinases 1 and 2 (ERK1/ERK2), are the most frequent dysregulated kinase pathways in GBM cells. While a direct mutation in the genes encoding ERK 1 and ERK 2 were not found to determine the aforementioned GBM subtypes, studies show that ERK1/2 is activated by phosphorylation in GBM, especially in the mesenchymal subtype (3) , and also in several other solid tumors (4) (5) (6) (7) (8) (9) (10) . Usually, levels of active ERK1/2 (p-ERK1/2) have been correlated with progression (11) and it is consistent throughout tumor entities that high levels of p-ERK are associated with shorter overall survival and higher proliferation indices (12) .
ERK was originally identified in 1991 by Cobb et al (13) and occurs in 2 isoforms, ERK1 and ERK2, which are homologous by 85% (14) . ERK1/2, abbreviated in the following with ERK, can be activated by phosphorylation of the TEY motif (threonine 202 and tyrosine 204; Fig. 1 ). ERK is next to p38 and JNK, a member of the MAPK family. MAPK signaling cascades transfer signals of extracellular stimuli via intracellular signal transduction to control fundamental cellular processes. In all cases, the signaling cascade consists of various kinases-conveniently called MAPKKK, MAPKK, and MAPK-between which the signal is transduced by phosphorylation and amplified each time (15, 16) .
Within the ERK signaling cascade, an extracellular signal is recognized by a corresponding receptor that undergoes conformational changes and activates the small GTPase RAS at the plasma membrane. RAS recruits MAPKKK, in this case RAF, to the membrane and activates RAF by an unknown mechanism. Activated RAF in turn can activate MEK-the MAPKK-by phosphorylation of serine residues. Subsequently, MEK phosphorylates ERK on threonine (202) and tyrosine (204) residues to yield activated p-ERK (15) .
This canonical pathway is hyperactivated in 85% of all cancers mostly due to mutations in RAS, RAF, or MEK. However, aberrant ERK has also been found in cancers driven by other nonpathway-related mutations such as PI3K/AKT, clearly stating that activated ERK1/2 is required for cellular transformation (14, 17) .
The active isoforms of ERK 1 and ERK2 can interact with >300 specific phosphorylation substrates localized in the cytoplasm, nucleus and other cellular organelles such as mitochondria, Golgi, endosomes, and lysosomes. By phosphorylation of these numerous substrates, ERK1/2 share a key role in the control of several cellular processes. Elk-1 (17), c-Fos (17), c-Jun (18), c-Myc (19) , Smad (20) , STAT (21), IEX-1 (22) , and MSK (23) are substrates involved in proliferation, whereas substrates controlling differentiation are IL4 (24), PDE4 (25) , FoxO3a (26, 27) , AML1 (28) , and Neurofilament (29) . Erk1/2 control stress response via hypoxia-inducible factor 1a (HIF-1a) (30) , ATF2 (31), cFos (32), HSF1 (33) , cMyc (34) , DAPK (35) , p66shcA (36) , and invasion via FAK (37), paxillin (37) , MMP (38) , vinexin (39) . Finally, ERK1/2 influences substrates responsible for apoptosis such as HABP1 (40) , Bad (41), Bim (42), Caspase9 (43), MCL1 (44) , TNFR CD120a (45), and HnRNP-K (46, 47) . The complex interaction network of ERK1/2 is illustrated in Figure 2 .
From this plethora of substrates one exemplified role of ERK1/2 in a cancer-related pathway is the regulation of transcription factor Elk1 in the cell nucleus. ERK1/2 can directly bind to Elk1 mediated by 2 binding sites and phosphorylates Elk1 at 6-9 distinct residues. Activated Elk1 can regulate immediate early genes such as c-Fos. After transcription c-Fos is highly unstable until it is phosphorylated by ERK, so that ERK not only induces transcription of the proto-oncogene cFos through Elk1 but also protects c-Fos from rapid degradation. Besides c-Jun, c-Fos is the counterpart of the dimerized transcription factor AP1, which regulates several genes including cell cycle regulators such as cyclin D (17) .
ERK IN TUMOR CELL PROLIFERATION
Constitutive MAPK signaling is a primary driver of cell proliferation in most cancer types (48) . Active p-ERK affects numerous essential processes for proliferation, such as Elk-1, which stimulates the production of pyrimidine nucleotides required for DNA synthesis during proliferation, influences chromatin remodeling, induces ribosome synthesis, and more (48) . For these processes, a common prerequisite is that p-ERK enters the cell nucleus (49) .
One of the best-described mechanisms of ERK activation and subsequent induction of proliferation is the classical RAS/RAF/MEK pathway as a result of stimulation with mitogens such as epidermal growth factor (EGF). Since this is well-known, we introduce some of the various other ways ERK and its proproliferative impact can be activated specifically in GBM.
Two research groups analyzed the tumor suppressor leucine rich repeat C4 protein (LRRC4) and its negative regulation of ERK. It was found that LLRC4 anchors ERK in the cytoplasm and competitively inhibits binding of MEK to ERK, thereby preventing phosphorylation of ERK and inhibiting proliferation. Considering that LRRC4 is downregulated in gliomas and even deleted in most GBMs, re-expression of LLRC4 offers a promising treatment option (50, 51) .
A positive correlation between proliferation and expression of the "ring finger protein" 135 (RNF135) was established for RNF135 which is upregulated in GBM compared with normal brain tissue. Clinically, high RNF135 expression is associated with poorer survival of glioma patients, on average median survival was 80 months shorter. Consequently, when RNF135 was downregulated or even silenced in vitro, a significant suppression of cell proliferation was associated with decreased levels of p-ERK. The interaction between RNF135 and ERK was confirmed by immunofluorescence that revealed colocalization of both proteins. Certainly impressive are the in vivo experiments showing that U87MG cells bearing a RNF135 knockout resulted in substantially smaller tumor sizes in xenografted mice than in those receiving wildtype cells. RNF135 suppression leads to decreased tumor cell proliferation via inactivation of ERK, demonstrating once more that ERK is an attractive target for GBM treatment (52) .
Additionally, Huang et al analyzed the role of adenosine triphosphate sensitive potassium (KATP) channels in proliferation of GBM cells. Inhibition of KATP channels led to decreased levels of p-ERK and subsequently decreased proliferation of GBM cells in vitro. Also, KATP inhibition slowed the formation of tumors in nude mice after injection of GBM cells. In contrast, activation of KATP channels had reverse effects, that is, an increase in p-ERK levels and proliferation in vitro and promotion of tumor development in vivo. To demonstrate the role of ERK in this context, inhibition of ERK abolished the effects of KATP channel opening on proliferation. Although the precise mechanism of interaction between KATP channels and ERK is not known to date, these results and the high abundance of KATP channels in glioma tissue compared with normal tissue specimen indicate a clinical relevance (53).
These 3 mechanisms described above could not be more diverse but they converge at the level of ERK activation. Because of the key role of ERK in these processes related to GBM, it seems feasible to target ERK as a promising option for the treatment of GBM patients.
ERK IN TUMOR CELL INVASION
Invasion of GBM cells into surrounding brain tissue occurs very often and defines an unmet need in GBM therapy to prevent massive infiltration of tumor cells in the early phase of tumor development. The ability to degrade components of the extracellular matrix is an essential feature of tumor cells. Although diverse, most extracellular matrix components can be degraded by enzymes of the matrix metalloproteinase (MMP) family, which are zinc-dependent endopeptidases. Various MMPs are highly expressed in malignant gliomas and for some MMPs, a correlation between their expression and tumor progression has been reported (54, 55) .
Several studies show that active ERK can regulate MMP genes on the transcriptional level, such as MMP-9. MMP-9, a MMP of 92 kDa, has been intensively analyzed in GBM and, to name 1 example, contributes to GBM cell invasion by cleavage of the cell-surface receptor CD44 (56) . A direct connection between active ERK, MMP-9 enzyme activity and the invasive potential of GBM cells using a dominant-negative ERK variant missing the kinase domain was reported (38) .
Intensive research was conducted on how this interaction occurs. It seems that microRNAs (miRNAs), small, noncoding RNAs of 22 nucleotides can regulate MMP-9 expression. It was demonstrated that the miRNA miR203 affects the p-ERK/MMP-9 signaling axis. Expression of miR203 is significantly attenuated in GBM compared with normal brain tissue. Re-expression of miR203 in GBM cells did not only cause a reduction of their invasive capability by 70% but also a reduction of p-ERK and MMP-9 by as much as 70% and 65%, respectively. This effect was reversed by restoration of ERK activity, clearly demonstrating a direct link between miR203, ERK activation, MMP-9 and its effect on the invasive potential of GBM cells (57) .
Similar findings were reported for other miRNAs. For instance, miR126 is downregulated in gliomas compared with normal tissue and correlates with malignancy, leaving GBM with the lowest level of miR126. By targeting KRAS, miR126 indirectly regulates p-ERK levels-the less miR126, the more p-ERK-and thereby MMP-9 levels as well as the invasive capability of GBM cells (55) .
Apart from miRNAs there are other factors linking ERK activity with MMP-9 expression, for example reactive oxygen species (ROS). When using 12-O-Tetradecanolylphorbol-13-acetate (TPA), a tumor promoter, higher levels of ROS together with induction of p-ERK and MMP-9 enzyme activity was observed. In addition, simultaneous treatment with TPA and ERK inhibitor (PD98059) reduced both MMP-9 activity and MMP-9 mRNA expression. Furthermore, anti-oxidants suppressed the effect of TPA, suggesting that the local oxygen concentration, determining the ROS content, has an impact on GBM progression by regulating ERK activity and its downstream effectors (58) .
To conclude, several factors affect the invasive potential of GBM cells and the common feature is the effect of active ERK on MMPs qualifying ERK as potential GBM therapy target to decrease GBM cell invasion of the surrounding brain tissue.
ERK IN STRESS RESPONSES TO HYPOXIA
Among the "hallmarks of cancer" involving activation of ERK is the tumor cell response to hypoxia. Hypoxia as deprivation of the adequate oxygen supply can provoke oxidative stress in cells. One prominent reaction of cells to hypoxic stress is, next to induction of the hypoxia-inducible factor 1 (HIF-1), the production of ROS and both are interacting with each other (59, 60) . ROS are produced by mitochondria and are an endogenous source of DNA damage leading to genomic instability in hypoxic regions (61) (62) (63) .
Hypoxia is a "chronic state" in most GBMs (64, 65) , contributes to progression and increases the probability of tumor recurrence by inducing neo-angiogenesis. A key molecule for tumor angiogenesis is vascular endothelial growth factor (VEGF) (63) , which leads to activation of endothelial cell and causes increased vascular permeability resulting in a highly abnormal vasculature with leaky and inefficient vessels. Furthermore cycling hypoxia, meaning spatial and temporal fluctuations in oxygen levels, limits the tumor response to chemoand radiotherapy in GBM (30, 68) .
Cells in hypoxic areas can either undergo cell death, that is, apoptosis or necrosis (67), or provoke an adaptive response that includes increasing rates of glycolysis and angiogenesis leading to selection of death resistant cells (69, 70) . This way both, chronic and cycling hypoxia, are driving forces in selecting more aggressive GBM phenotypes.
The responsible factor regulating the ability of tumor cells to maintain a balance between adaption to hypoxia or undergoing cell death are HIFs. HIFs are responsible for the expression of hypoxia-responsive genes, including erythropoietin, transferrin and its receptor, VEGF and its receptor, and glucose transporters (66) . HIF-1 is a heterodimer consisting of a HIF-1a and a HIF-1b subunit. While the b subunit is constitutively expressed, the a subunit accumulates in the nucleus when there is hypoxic stress. Therefore, HIF-1 is highly expressed in hypoxic foci within tumors.
Previous studies revealed that repetitive periods of hypoxia and reoxygenation in vitro could lead to an increased production of ROS (71), which is responsible for induction of HIF-1 in GBM (72) . It was initially shown that HIF-1 can mediate radio-resistance (73) , that is, Hsieh et al showed that cycling hypoxia induced radio-resistance in U87 GBM cells that resulted in a decreased response to radiotherapy. However, a knockdown of HIF-1 during hypoxic stress suppressed this cycling hypoxia-induced radio-resistance and consequently increased tumor radio-sensitivity (72) .
As a reduced supply with nutrients does not only result in hypoxia but also in a low pH in the tumor environment, it is interesting to note that low pH can also activate the ERK-MAPK pathway and leads to increased VEGF expression in U87MG cells that is associated with a poor outcome in GBM (74) .
Additional studies showed that ERK plays a pivotal role in hypoxia selection and resistance (75) . For instance, hypoxia-resistant T98G GBM cell clones were generated that expressed higher levels of p-ERK and anti-apoptotic proteins such as Bcl-2 and Bcl-X than the parental cells. It is known that ERK is an early responder to hypoxic conditions. Data from Kim et al indicate that ERK activation upon cycling hypoxia might be mediated by the small GTPase Ras in a ROSdependent pathway.
Regarding the effect of hypoxia on ERK-mediated induction of invasion, it was shown that cycling hypoxia upregulates the expression of MMP9 via a ROS-mediated activation of ERK (76) . This confirms a link between cycling hypoxia and ERK activation that in turn leads to secretion and activation of MMP9 and causes increased invasion in vitro and in vivo upon cycling hypoxia. This "vicious circle" appears relevant for treatment options in GBM to overcome GBM recurrence.
Activation of ERK can be directly affected by radiation upregulation of p-ERK upon radiation under hypoxic conditions was observed30. In line with this, inhibition of MEK/ ERK had radio-sensitizing effects on different GBM cell lines under hypoxic conditions (30) . ERK is activated during hypoxia and positively regulates HIF-1a expression. Additionally, ERK seems to be responsible for phosphorylation of HIF-1a required for transcriptional activity. Consequently, inhibition of MEK/ERK could reduce an increase in HIF-1a activity under hypoxic conditions, an important regulator of GBM radioresistance.
In addition to the effect of ERK1/2 on radiosensitivity, there might also be a link between ERK and chemo-resistance in hypoxia. It was found that hyperoxia could enhance the temozolomide (TMZ) toxicity in GBM cells by inducing apoptosis, most likely regulated by ERK-related pathways (77) . Also TMZ can enhance ERK activation via ADAM8, an extracellular metalloprotease involved in cell-cell signaling (78) .
Interestingly, Soeda et al showed that hypoxia promotes the self-renewal of glioma-derived cancer stem cells (CSCs) which was observed in correlation with an upregulation of HIF-1a (79) . Knock-down of HIF-1a and inhibition of the ERK pathway resulted in abrogation of CSC growth. This strongly suggests that ERK signaling modulates hypoxia driven expansion of CSCs.
Taken together, these initial studies highlight the relevance of ERKs in mediating the radio-and chemoresistance of GBM cells under hypoxic conditions. Since hypoxia is a major hallmark of GBMs and is responsible for the resistance to recent therapies, it is of great interest to find a potential therapeutic target that overcomes this hypoxia-mediated resistance.
Because of its role in hypoxia, ERK might be an interesting candidate to achieve this aim.
ERK IN APOPTOSIS
The intrinsic and extrinsic pathways are 2 main mechanisms to induce apoptosis and both pathways require ERK. The intrinsic pathway is regulated by proteins of the Bcl-2 family with involvement of mitochondrial membrane potential and release of cytochrome c from the intermembrane space. Cytochrome c and Apaf1 form an apoptosome able to activate caspase9 that activates caspase3. In contrast, the extrinsic pathway is regulated by extracellular death ligands binding to receptors of the tumor necrosis factor (TNF) receptor family. Upon ligand binding, cytoplasmic adapter proteins form the death-inducing signaling complex (DISC). DISC enables auto-catalytic activation of caspase 8, an initiator caspase, which in turn activates the executioner caspase3. Thus, both pathways lead to activation of caspase3, a key molecule in apoptotic processes. Caspase3 may initiate the cellular response for example by activating caspase activated DNase (CAD), and endonuclease, which are able to degrade chromosomal DNA (80, 81) .
Among death ligands, TNF related apoptosis inducing ligand (TRAIL) is mainly expressed by immune cells and induces apoptosis of tumor cells. Resistance against TRAIL has been found in human GBM cells (82) with p-ERK linked to TRAIL resistance. Application of lovastatin, an approved cholesterol lowering drug, resensitized GBM cells to TRAIL and caused higher rates of cell cycle arrest and apoptosis but lower levels of p-ERK. Although mechanistically unclear, these results suggest that lovastatin in combination with TRAIL has the ability to block tumor growth by inhibiting ERK and promoting tumor cell apoptosis, implicating a substantial clinical relevance (83) .
In the intrinsic pathway, ERK can regulate the proapoptotic protein Bim: Phosphorylation of Bim by p-ERK leads to its rapid degradation, so that ERK inhibition causes Bim accumulation and activates apoptosis (42, 84) . This association was exploited in a study showing the therapeutic potential of the sphingosine analogue FTY720 to treat GBM (85) . As a result of this study, reduction of p-ERK upon treatment with FTY720 and accumulation of Bim caused increased apoptosis in primary GBM tumor stem cells. Furthermore, a synergistic effect between FTY720 and TMZ was seen in vitro and in vivo by measuring cell viability and survival of xenografted mice, respectively (85) . It is interesting to note that FTY720 is already FDA approved for treatment of relapsing multiple sclerosis (86) .
ROLE OF ERK IN INDUCING TUMOR CELL DIFFERENTIATION
The stage of differentiation is a central parameter for histopathological classification and grading of solid malignancies (87) . For a long time, it was considered as a unidirectional process but currently controversy exists around this topic and the question whether tumor cells can dedifferentiate.
Several studies showed that inhibition of MEK/ERK leads to increased differentiation in glioma cells in general (88) and GBM cells more specifically (26, 27, 89, 90) . First, the increase in differentiation was determined by sphere formation assays of stem-like GBM cells and by an increase in differentiation specific markers such as glial fibrillary acidic protein and bIII-tubulin. Second, the degree of differentiation was characterized by the decrease of stemness associated markers, including nestin and Sox2, and by decreased tumorigenicity.
Sunayama et al and Yang et al proposed a mechanism for this phenomenon. Upon inhibition of MEK/ERK they observed an increase in FoxO3a expression level. Both groups showed that p-ERK phosphorylates FoxO3a at specific sites thereby initiating the transport of p-FoxO3a from the nucleus to the cytoplasm where FoxO3a can no longer regulate its target genes. The results are well-documented by diverse experimental approaches, including the use of a mutated FoxO3a without the specific phosphorylation site, a knockdown of FoxO3a, and dominant negative forms of ERK, all leading to the same result: Active ERK suppresses the stability of FoxO3a resulting in a decrease in differentiation and an increase in self-renewal and tumorigenicity of GBM cells. Hence, ERK inhibition leads to increased FoxO3a expression levels promoting differentiation (26, 27) demonstrating that ERK serves an essential pathway to control the stem cell character of GBM cells.
Sato et al also found that MEK/ERK inhibition leads to differentiation of GBM cells, although they subsequently did not analyze the underlying mechanism but the concomitant cellular response. This enabled them to find that MEK/ERK inhibition did not only result in differentiation of GBM cells but also in reduced O6-methylguanine-DNA-methyltransferase (MGMT) expression (90) . This is of special interest considering that MGMT activity is the main predictor of TMZ resistance in GBM patients. These results highlight the potential of ERK inhibition in combination with TMZ.
A link between differentiation of CSCs in glioma and ERK was shown by Soeda et al (79) . The authors showed that hypoxia is capable of inhibiting differentiation of CSCs. Also, inhibition of ERK abolished the growth of undifferentiated CSCs under hypoxic conditions and induced their differentia- All listed compounds are able to cross the blood-brain barrier.
tion. Since it is widely believed that hypoxia is important for maintaining CSCs in their undifferentiated state thus preserving their proliferative capacities, these results intriguingly suggest ERK as an important player in maintaining the niche of undifferentiated CSCs. Since differentiation therapy is an emerging field in cancer treatment with current ongoing research effort, targeting ERK to control CSC differentiation in GBM could be an attractive therapeutic strategy.
CLINICAL POTENTIAL OF ERK INHIBITION
Given the overwhelming evidence for the involvement of ERK in many cellular events in high-grade glioma, ERK inhibition in this tumor entity appears promising. In the past, there has been limited progress in development of ERK selective inhibitors, in contrast to the advanced clinical development of RAF and MEK inhibitors, which are not discussed here. However, recently, efforts to develop ERK inhibitors have increased as targeting ERK directly suppresses the main effector of the MAPK pathway and thereby leads to maximum efficacy and avoids therapy resistance. Currently, some inhibitors are being tested in clinical trials. Although none of them is specifically designed for targeting GBM, no exclusion criteria exist for GBM patients since all inhibitors mentioned here can pass through the blood-brain barrier. Currently, patients are recruited with locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable (Clinical Trial: A Dose-Escalation Study of GDC-0994 in Patients with Locally Advanced or Metastatic Solid Tumors).
One of the most promising ERK inhibitors is SCH772984 (Merck/Schering Plough, Munich, Germany), which was identified in 2013 through an affinity based mass spectroscopy high throughput platform in which 5 million compounds were tested for their ability to bind to unphosphorylated ERK (91) . SCH772984 was found to be highly specific-only 7 out of 300 kinases showed >50% inhibition at a concentration of 1 mM. SCH772984 was found to inhibit ERK 1 and ERK 2 with an IC50 of 4 nM and 1 nM, respectively. Interestingly, SCH772984 is able to inhibit ERK by a dual mechanism. On the one hand, SCH772984 is an ATP-competitive inhibitor, consequently inhibiting the intrinsic kinase activity of ERK. On the other hand, SCH772984 prevents phosphorylation of ERK by MEK by inducing a conformational change of ERK. SCH772984 is also effective in BRAF and KRAS mutant cells in vitro and in vivo, leading to a 98% tumor regression in BRAF mutant melanoma xenografts. In these experiments, the inhibitor was well-tolerated at the given dosage of 50 mg/kg. Since one of the biggest limitations of RAF and MEK inhibitors is the development of resistance and reactivation of ERK, the clinically most rele- vant result is the fact that SCH772984 has proven to inhibit ERK in cells that have become resistant to BRAF and MEK inhibitors such as PLX4032 and GSK1120212. These promising results are the reason why MK-8353/SCH900353, a clinical grade analogue of SCH772984, is currently being tested in phase I clinical trials on patients with advanced solid tumors (91, 92) .
Another ERK inhibitor currently in a similar phase I clinical development is the orally available GDC-0994 (Genentech/Roche, South San Francisco, CA). This inhibitor showed promising results in KRAS mutant colorectal cancer xenografts that resulted in a significant tumor growth inhibition (93) . Also in clinical trials for patients with advanced malignancies is BVD-523/Ulixertinib (BioMed Valley Discoveries, Kansas City, MO), which has been reported to be a potent, selective small molecule with impressive in vitro and in vivo preclinical efficacy (94). Although its DMPK data are not publically available in the public domain, it can be expected to be effective in tumors where MAPK pathway addiction has been demonstrated (92, 94) .
As of 2017, KO-947 (Kura Oncology, San Diego, CA) is in a clinical trial; it seems to be a potent inhibitor of ERK signaling that can reduce tumor cell proliferation in cells exhibiting dysregulation of the MAPK pathway, for example, due to mutations in BRAF, NRAS, or KRAS. More precisely, KO-947-induced tumor regression in models lacking BRAF/ RAS mutations, (but which are characterized by other dysregulation of the MAPK pathway), as well as in BRAF mutant melanoma and KRAS mutant NSCLC xenograft mouse models; it was also active in KRAS or BRAF mutant colon, lung and pancreatic PDX models. Moreover, in preclinical testing, KO-947 seemed to be well-tolerated and demonstrated prolonged pathway modulation, suggesting the possibility for flexible treatment regimens (95, 96) . (97) , and FR180204 (Tocris) (98) . The latter was discovered by a high throughput phosphorylation assay testing compounds with the ability to inhibit ERK mediated phosphorylation of myelin basic protein (MBP). FR180204 belongs to the ATP competitive ERK inhibitors and is selective over a series of other kinases-it shows a 30-fold higher selectivity for ERK than for p38a and a 100-fold higher selectivity for ERK than for other kinases, including MEK. Interestingly, a derivative of the inhibitor without the amino group at the 3 0 position (FR180289) shows no inhibitory potential suggesting that a hydrogen bond between this very group and carbonyl groups of both the Gln 105 and Asp 106 residues of the ATP binding domain of ERK is essential for the inhibitory effect. This compound could serve as a control in further analysis of FR180204 (99, 100) .
Given the series of potent ERK inhibitors and the essential role of ERK in GBM pathophysiology, we conclude that GBM patients would benefit from ERK inhibition. We showed that there are several promising compounds (Table) , of which some are currently being tested in clinical trials, and we believe that this is the first step to a new therapeutic approach to target ERK for the successful treatment of GBM.
Conclusion
As members of the MAPK family, ERK1 and ERK2 are involved in several cellular events regulating proliferation, differentiation, stress response, invasion, and apoptosis. This review shows that ERK participates in many hallmarks of high-grade glioma such as tumor cell invasion, response to hypoxic stress and preservation of CSCs, all critical factors that need to be addressed in the therapy of GBM (Fig. 3) . The clinical hypothesis is that inhibiting ERK either alone or in combination with adjuvant therapies decreases the ability of GBM cells to invade, to survive radiation under hypoxic conditions and to reduce stem cell populations. Thus, one would expect that ERK inhibition would at least induce a delay of tumor recurrence and further sensitize tumor cells and CSCs to radio-and chemotherapy.
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